Temocapril

This classification denotes an angiotensin-converting enzyme inhibitor and antihypertensive agent with the molecular formula C23H28N2O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 18IZ008EU6, chemically known as 1,4-thiazepine-4(5h)-acetic acid, 6-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-, (2s-(2alpha,6beta(r*)))- but generally known as temocapril, which bears US NIH Compound Identifier 71323. European Medicines Agency schedules Temocapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10884MIG. World Health Organization schedules temocapril in its Anatomical Therapeutic Chemical (ATC) Classification. TEMOCAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule temocapril under HS 29349990 and SITC 51579. As of Q4 2014, TEMOCAPRIL remains the US FDA Preferred Term for this commodity. Temocapril bears US NLM identifiers UMLS ID C0753183 and NCI Concept Code C99555. SMILES: S1C(CN(C(=O)C(NC(CCc2ccccc2)C(=O)OCC)C1)CC(=O)O)c1sccc1.